Table 1.
Baseline characteristics of included patients in the HEPAR-PLuS trial
| N (%) | |
|---|---|
| Number of patients | 31 |
| Age—Median (IQR) | 65.1 (57.6–70.2) |
| Gender | |
| Male | 23 (74.2%) |
| Female | 8 (25.8%) |
| Origin of tumor | |
| Pancreas | 10 (32.3%) |
| Small intestine | 8 (25.8%) |
| Colorectal | 4 (12.9%) |
| Lung | 3 (9.7%) |
| Unknown primary | 6 (19.4%) |
| WHO Grade | |
| 1 | 12 (38.7%) |
| 2 | 19 (61.3%) |
| Weeks since final cycle PRRT—Median (IQR) | 12.7 (9.7–15.8) |
| ECOG status | |
| 0 | 17 (54.8%) |
| 1 | 13 (41.9%) |
| 2 | 1 (3.2%) |
| Total liver dose in Gy—Median (IQR)a | 46.4 (41.2–55.1) |
| Tumor burden in %—Median (IQR) | 6.9% (3.1–22.5%) |
| Extrahepatic disease | |
| Absent | 11 (35.5%) |
| Lymph nodes | 5 (16.1%) |
| Visceral | 6 (19.4%) |
| Lymph nodes and visceral | 9 (29.0%) |
| Baseline NLR—Median (IQR) | 4.3 (3.6–5.7) |
| Baseline TLR—Median (IQR) | 238 (176–308) |
IQR interquartile range
aAbsorbed dose as calculated based on the total liver volume and the total infused activity. This does not equal 60 Gy in all patients due to not all patients receiving a total liver treatment